Cargando…

Case Report of Thymoma Tumor Reduction Following Plasmapheresis

For thymoma, multidisciplinary antitumor strategy is composed of surgery, chemotherapy, and radiotherapy. Meanwhile, ∼20% to 25% of patients with thymoma have myasthenia gravis and plasmapheresis is recommended for thymoma-associated myasthenia gravis. We report a case that a 40-year-old woman with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wei, Yu, Qitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059021/
https://www.ncbi.nlm.nih.gov/pubmed/26632752
http://dx.doi.org/10.1097/MD.0000000000002173
_version_ 1782459359764152320
author Jiang, Wei
Yu, Qitao
author_facet Jiang, Wei
Yu, Qitao
author_sort Jiang, Wei
collection PubMed
description For thymoma, multidisciplinary antitumor strategy is composed of surgery, chemotherapy, and radiotherapy. Meanwhile, ∼20% to 25% of patients with thymoma have myasthenia gravis and plasmapheresis is recommended for thymoma-associated myasthenia gravis. We report a case that a 40-year-old woman with thymoma experiencing tumor relapse after surgery showed significant response to plasmapheresis. This is the first case of thymoma responded to plasmapheresis, which may guide the study of the etiology and pathogenesis of thymoma.
format Online
Article
Text
id pubmed-5059021
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-50590212016-11-01 Case Report of Thymoma Tumor Reduction Following Plasmapheresis Jiang, Wei Yu, Qitao Medicine (Baltimore) 5700 For thymoma, multidisciplinary antitumor strategy is composed of surgery, chemotherapy, and radiotherapy. Meanwhile, ∼20% to 25% of patients with thymoma have myasthenia gravis and plasmapheresis is recommended for thymoma-associated myasthenia gravis. We report a case that a 40-year-old woman with thymoma experiencing tumor relapse after surgery showed significant response to plasmapheresis. This is the first case of thymoma responded to plasmapheresis, which may guide the study of the etiology and pathogenesis of thymoma. Wolters Kluwer Health 2015-10-30 /pmc/articles/PMC5059021/ /pubmed/26632752 http://dx.doi.org/10.1097/MD.0000000000002173 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Jiang, Wei
Yu, Qitao
Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title_full Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title_fullStr Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title_full_unstemmed Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title_short Case Report of Thymoma Tumor Reduction Following Plasmapheresis
title_sort case report of thymoma tumor reduction following plasmapheresis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059021/
https://www.ncbi.nlm.nih.gov/pubmed/26632752
http://dx.doi.org/10.1097/MD.0000000000002173
work_keys_str_mv AT jiangwei casereportofthymomatumorreductionfollowingplasmapheresis
AT yuqitao casereportofthymomatumorreductionfollowingplasmapheresis